1. Home
  2. BGLC vs LCFY Comparison

BGLC vs LCFY Comparison

Compare BGLC & LCFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BGLC
  • LCFY
  • Stock Information
  • Founded
  • BGLC 2017
  • LCFY 2009
  • Country
  • BGLC Malaysia
  • LCFY Australia
  • Employees
  • BGLC N/A
  • LCFY N/A
  • Industry
  • BGLC Medical Specialities
  • LCFY
  • Sector
  • BGLC Health Care
  • LCFY
  • Exchange
  • BGLC Nasdaq
  • LCFY Nasdaq
  • Market Cap
  • BGLC 10.4M
  • LCFY 9.2M
  • IPO Year
  • BGLC N/A
  • LCFY 2022
  • Fundamental
  • Price
  • BGLC $5.53
  • LCFY $5.31
  • Analyst Decision
  • BGLC
  • LCFY
  • Analyst Count
  • BGLC 0
  • LCFY 0
  • Target Price
  • BGLC N/A
  • LCFY N/A
  • AVG Volume (30 Days)
  • BGLC 178.0K
  • LCFY 139.1K
  • Earning Date
  • BGLC 11-14-2025
  • LCFY 11-11-2025
  • Dividend Yield
  • BGLC N/A
  • LCFY N/A
  • EPS Growth
  • BGLC N/A
  • LCFY N/A
  • EPS
  • BGLC N/A
  • LCFY N/A
  • Revenue
  • BGLC $9,551,559.00
  • LCFY $2,231,313.00
  • Revenue This Year
  • BGLC N/A
  • LCFY N/A
  • Revenue Next Year
  • BGLC N/A
  • LCFY N/A
  • P/E Ratio
  • BGLC N/A
  • LCFY N/A
  • Revenue Growth
  • BGLC 4.01
  • LCFY N/A
  • 52 Week Low
  • BGLC $2.01
  • LCFY $2.51
  • 52 Week High
  • BGLC $15.60
  • LCFY $13.98
  • Technical
  • Relative Strength Index (RSI)
  • BGLC 47.38
  • LCFY 41.23
  • Support Level
  • BGLC $5.19
  • LCFY $3.86
  • Resistance Level
  • BGLC $5.47
  • LCFY $7.67
  • Average True Range (ATR)
  • BGLC 0.33
  • LCFY 0.81
  • MACD
  • BGLC -0.04
  • LCFY -0.20
  • Stochastic Oscillator
  • BGLC 11.17
  • LCFY 42.25

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

About LCFY Locafy Limited

Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.

Share on Social Networks: